Abstract:Objective:To evaluate the long-term risk of rebleeding in patients with acute esophageal and gastric variceal bleeding and portal vein thrombosis after endoscopic treatment in liver cirrhosis.Methods:From January to December 2022, 57 patients with acute esophageal and gastric variceal bleeding who were treated by endoscopy in the emergency department of the Zhongshan Hospital affiliated to the Fudan University were included in the study. According to the results of portal vein CT angiography (CTA), the patients were divided into thrombosis group and non thrombosis group. We compared the basic information and endoscopic treatment status of two groups of patients. All patients were followed up until 1 year after endoscopic treatment or April 15, 2023, and re bleeding and survival were recorded during the follow-up period. The influencing factors of rebleeding after 1 year of treatment were analyzed.Results:The patient′s age was (55.9±11.4)years old, mainly male [78.95%(45/57)]. The average time from initial bleeding to endoscopic treatment for all patients was (6.6±2.8)days. There was no statistically significant difference between the two groups in terms of age, sex, combined liver malignancy, Child-pugh score, first bleeding form, ascites, and first laboratory examination results (including hemoglobin, platelet, Prothrombin time, creatinine) (all P>0.05). There was no statistically significant difference in the history of endoscopic treatment, bleeding distance from endoscopic treatment, the proportion of patients with esophageal varices and gastric varices, the proportion of patients with esophageal varices treated with ligation, and the proportion of patients with gastric varices treated with tissue glue between the two groups (all P>0.05). A total of 2 patients died after surgery, and 12 patients experienced rebleeding, including 10 in the thrombotic group and 2 in the non thrombotic group. Kaplan Meier analysis showed that the 1-year rebleeding rate in the thrombotic group was significantly higher than that in the non thrombotic group (59.02% vs 24.71%, RR=6.002, 95% CI: 1.06-34.00, P=0.020 8). Cox multivariate regression analysis suggests that the presence of portal vein thrombosis ( HR=7.669, 95% CI: 1.453-40.472, P=0.016) was an independent risk factor for recurrent bleeding after endoscopic treatment of acute esophageal and gastric variceal bleeding for one year. Conclusions:Portal vein thrombosis in liver cirrhosis increases the risk of recurrent bleeding after endoscopic treatment for acute esophageal and gastric variceal bleeding for one year. For patients with acute Upper gastrointestinal bleeding complicated with portal vein thrombosis, regular endoscopic and ultrasonic follow-up, individualized endoscopic sequential and selective anticoagulation therapy should be carried out.

Types of Esophagogastric Varices in Portal Hypertension Patients with Upper Gastrointestinal Rebleeding after Splenectomy and Devascularization

[Comparison of Characteristics of Esophageal Gastric Varices in Portal Hypertension Patients with and Without Spontaneous Shunts].

Laparoscopic splenectomy plus pericardial devascularization for the treatment of portal hypertension in cirrhotic patients

Influence of follow-up treatment compliance on prognosis after endoscopic gastroesophageal varices treatment

Separate control of the splenic artery and vein in laparoscopic splenectomy and pericardial devascularization for the treatment of portal hypertension

Risk Factors for Predicting Early Variceal Rebleeding after Endoscopic Variceal Ligation

[Laparoscopic Splenectomy and Pericardial Devascularization for Treatment of Portal Hypertension Due to Liver Cirrhosis].

Splenectomy And Selectively Devascularization For Esophageal Bleeding Secondary To Portal Hypertension

Analysis on Therapeutic Effect of Selective Paraesophagogastric Devascularization Without Splenectomy for Treatment of Portal Hypertension with Upper Gastrointestinal Hemorrhage

Clinical Application of Gastroesophageal Varices Embolization Combined with Partial Splenic Embolization in Portal Hypertension

The clinical study of selective paraesophagogastric devascularization and splenectomy plus distal esophageal transection and reanastomosis with stapler for treatment of esophageal variceal bleeding due to portal hypertension

Two Surgical Procedures for Esophagogastric Variceal Bleeding in Patients with Portal Hypertension

The impact of portal vein thrombosis on the long-term efficacy of endoscopic treatment for acute esophageal and gastric variceal bleeding patients

Therapeutic Effect and Safety of Selective Paraesophagogastric Devascularization with or Without Splenectomy for Treatment of Esophagogastric Variceal Hemorrhage

Prognostic Capability of Portal Vein Thrombosis for Rebleeding in Cirrhotic Patients after Esophagogastric Devascularization and Splenectomy

Periesophagogastric devascularization without splenectomy in the treatment of portal hypertension

Clinical Factors That Influence the Outcome of Selective Devascularization in the Treatment of Portal Hypertension.

Endovascular Management of Sinistral Portal Hypertension-Related Variceal Hemorrhage: a Multicenter Retrospective Study.

Diagnosis and Treatment of Upper Gastrointestinal Hemorrhage Caused by Pancreatic Segmental Portal Hypertension

Esophagogastric Devascularization Without Splenectomy in Portal Hypertension: Safe and Effective?

Portal Vein Thrombosis Can Aggravate Esophageal Variceal Bleeding After Endoscopic Variceal Ligation